Mary Carter
Family · Corinth, MSNPI 1316487994
Payments from drug & device makers
Across 120 payments — averaging $12.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$787
- Novo Nordisk$145
- Otsuka America Pharmaceutical, Inc.$76
- Esperion Therapeutics, Inc.$59
- AstraZeneca$55
- Biohaven Pharmaceutical Holding Company Ltd.$52
- plus $311 from 13 others
What the payments were for
- Food & beverage$1,485100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $787 |
| Novo Nordisk | 10 | $145 |
| Otsuka America Pharmaceutical, Inc. | 5 | $76 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| AstraZeneca | 4 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Pfizer | 3 | $46 |
| GSK | 3 | $44 |
| Amgen | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $17 |
| Sandoz | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Abbott | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$110
How this compares
$1,485 in reported general payments places this provider in the 75th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 59 | $60,535 |
| OzempicSemaglutide | 51 | $57,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $53,658 |
| JardianceEmpagliflozin | 47 | $52,727 |
| FarxigaDapagliflozin Propanediol | 23 | $29,274 |
| EliquisApixaban | 34 | $28,362 |
| LinzessLinaclotide | 16 | $20,878 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $15,335 |
| XareltoRivaroxaban | 13 | $13,619 |
| EntrestoSacubitril/Valsartan | 13 | $13,471 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $10,554 |
| Potassium Chloride | 70 | $4,722 |
| Dexlansoprazole DrDexlansoprazole | 20 | $4,199 |
| Gabapentin | 130 | $2,052 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $13 | $60,53559 claims |
| Novo NordiskOzempic | $145 | $57,86551 claims |
| GSKTrelegy Ellipta | $44 | $53,65851 claims |
| Boehringer IngelheimJardiance | $26 | $52,72747 claims |
| AstraZenecaFarxiga | $55 | $29,27423 claims |
| PfizerEliquis | $46 | $28,36234 claims |
| AbbVieLinzess | $787 | $20,87816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,007 family providers in Mississippi.
Other family in Corinth
- Phyllis FiveashCorinth$12K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.